Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Summary

The purpose of this research study is to evaluate the safety and effectiveness of CK-2017357 when taken with or without riluzole (also called Rilutek®) in patients with Amyotrophic Lateral Sclerosis (ALS).

Timeline

Start

2012-10

Primary completion

2014-03

Completion

2014-03

Outcome

Missed primary endpoint

registry analysis (superiority test); Placebo vs Tirasemtiv; p = 0.1140; Least squares mean difference -0.58 (95% CI -1.30 to 0.14) NCT01709149 ↗

Drugs

Indications